[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554833":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":211,"collaborators":10,"id":213,"slug":10,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":214,"sex":220,"minAge":221,"maxAge":10,"enrollmentInfo":222,"targetDuration":10,"studyType":225,"phases":10,"briefSummary":226,"conditions":227,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Active Comparator: Control",null,"Drug: Anti R-IL2 + Cyclosporine\n\n* Anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)\n* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0\n* Cyclosporine A (Neoral ®) started from 6 to 8 mg\u002Fkg adjusted to C2\n* Corticosteroids 250 mg IV before and after surgery, then 1 mg\u002Fkg one week and 20mg\u002Fj the week after, then tapered until 10 mg\u002Fj at M1, 5 mg at M3 and stop between M4 and M6",{"label":13,"type":10,"description":14,"interventionNames":10},"Experimental: CNI-free","Drug: Thymoglobulin + Everolimus\n\n* Thymoglobulin ® induction started at 1.5mg\u002Fkg\u002Fj then adjusted to CD2 or total lymphocytes count, for 5 days\n* Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0\n* Everolimus (Certican ®): 4 to 6 mg\u002Fday started at D5, adjusted to achieve a residual level between 6 et 10 ng\u002Fml\n* Corticosteroids 250 mg IV before and after surgery, then 1 mg\u002Fkg one week and 20mg\u002Fj the week after, then tapered until 10 mg\u002Fj at M1, 5 mg at M3 and stop between M4 and M6",{"label":16,"type":10,"description":17,"interventionNames":10},"Experimental: Switch","Drug: Anti R-IL2 + Cyclosporine then Everolimus\n\n* Anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)\n* Mycophenolate Mofetil (Cellcept ®) 3 g\u002Fd beginning at D0\n* Cyclosporine A (Neoral ®) beginning at 6 to 8 mg\u002Fkg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg\u002Fd, then adjusted to achieve a residual level between 6 et 10 ng\u002Fml\n* Corticosteroids 250 mg IV before and after surgery, then 1 mg\u002Fkg one week and 20mg\u002Fj the week after, then tapered until 10 mg\u002Fj at M1, 5 mg at M3 and stop between M4 and M6",[19],{"name":20,"affiliation":21,"role":22},"Yannick LE MEUR","CHU Brest","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Yannick Le Meur","CONTACT","+330298347014","yannick.lemeur@chu-brest.fr",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Christelle RATAJCZAK","+330298347061","christelle.ratajczak@chu-brest.fr",[34,50,62,73,86,99,110,119,132,145,159,172,185,198],{"facility":35,"status":36,"city":37,"state":10,"zip":10,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Chu Amiens","RECRUITING","Amiens","France",{"type":40,"coordinates":41},"Point",[42,43],2.3,49.9,{"lat":43,"lon":42},[46],{"name":47,"role":26,"phone":48,"phoneExt":10,"email":49},"Coralie POULAIN, Dr","03 22 45 58 60","coralie.poulain@chu-amiens.fr",{"facility":51,"status":36,"city":52,"state":10,"zip":10,"country":38,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"CHU Bordeaux","Bordeaux",{"type":40,"coordinates":54},[55,56],-0.58046,44.84124,{"lat":56,"lon":55},[59],{"name":60,"role":26,"phone":10,"phoneExt":10,"email":61},"Lionel COUZI, Pr","lionel.couzi@chu-bordeaux.fr",{"facility":63,"status":36,"city":64,"state":10,"zip":10,"country":38,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Chu Brest","Brest",{"type":40,"coordinates":66},[67,68],-4.48628,48.39029,{"lat":68,"lon":67},[71],{"name":72,"role":26,"phone":10,"phoneExt":10,"email":28},"Yannick LE MEUR, Pr",{"facility":74,"status":36,"city":75,"state":10,"zip":10,"country":38,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"CHU Lille","Lille",{"type":40,"coordinates":77},[78,79],3.05512,50.63391,{"lat":79,"lon":78},[82],{"name":83,"role":26,"phone":84,"phoneExt":10,"email":85},"Marc HAZZAN, Pr","03 20 44 59 62","marc.hazzan@univ-lille.fr",{"facility":87,"status":36,"city":88,"state":10,"zip":10,"country":38,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"CHU Limoges","Limoges",{"type":40,"coordinates":90},[91,92],1.24759,45.83362,{"lat":92,"lon":91},[95],{"name":96,"role":26,"phone":97,"phoneExt":10,"email":98},"Jean-Philippe REROLLE, Dr","05 55 05 55 55","jean-philippe.rerolle@chu-limoges.fr",{"facility":100,"status":36,"city":101,"state":10,"zip":10,"country":38,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"CHU Nice Pasteur 2","Nice",{"type":40,"coordinates":103},[104,105],7.26608,43.70313,{"lat":105,"lon":104},[108],{"name":109,"role":26,"phone":10,"phoneExt":10,"email":10},"Antoine SICARD, Pr",{"facility":111,"status":36,"city":101,"state":10,"zip":10,"country":38,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"CHU Nice",{"type":40,"coordinates":113},[104,105],{"lat":105,"lon":104},[116],{"name":109,"role":26,"phone":117,"phoneExt":10,"email":118},"03 80 29 30 31","sicard.a@chu.nice.fr",{"facility":120,"status":36,"city":121,"state":10,"zip":10,"country":38,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Hôpital Necker","Paris",{"type":40,"coordinates":123},[124,125],2.3488,48.85341,{"lat":125,"lon":124},[128],{"name":129,"role":26,"phone":130,"phoneExt":10,"email":131},"Dany ANGLICHEAU, Pr","01 44 49 40 00","dany.anglicheau@aphp.fr",{"facility":133,"status":36,"city":134,"state":10,"zip":10,"country":38,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Chu Poitiers","Poitiers",{"type":40,"coordinates":136},[137,138],0.34348,46.58261,{"lat":138,"lon":137},[141],{"name":142,"role":26,"phone":143,"phoneExt":10,"email":144},"Antoine THIERRY, Pr","05 49 44 44 44","antoine.thierry@chu-poitiers.fr",{"facility":146,"status":36,"city":147,"state":10,"zip":10,"country":38,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"CHU Rennes","Rennes",{"type":40,"coordinates":149},[150,151],-1.67431,48.11109,{"lat":151,"lon":150},[154],{"name":155,"role":26,"phone":156,"phoneExt":157,"email":158},"Elsa VABRET, Dr","02 99 28 43 21","+33","elsa.vabret@chu-rennes.fr",{"facility":160,"status":36,"city":161,"state":10,"zip":10,"country":38,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"CHU Rouen","Rouen",{"type":40,"coordinates":163},[164,165],1.09932,49.44313,{"lat":165,"lon":164},[168],{"name":169,"role":26,"phone":170,"phoneExt":10,"email":171},"Dominique BERTRAND, Dr","02 32 88 89 90","dominique.bertrand@chu-rouen.fr",{"facility":173,"status":36,"city":174,"state":10,"zip":10,"country":38,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"CHU Strasbourg","Strasbourg",{"type":40,"coordinates":176},[177,178],7.74553,48.58392,{"lat":178,"lon":177},[181],{"name":182,"role":26,"phone":183,"phoneExt":10,"email":184},"Sophie CAILLARD-OHLMANN, Pr","03 88 11 67 68","sophie.ohlmann@chru-strasbourg.fr",{"facility":186,"status":36,"city":187,"state":10,"zip":10,"country":38,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"CHU Toulouse Rangueil","Toulouse",{"type":40,"coordinates":189},[190,191],1.44367,43.60426,{"lat":191,"lon":190},[194],{"name":195,"role":26,"phone":196,"phoneExt":10,"email":197},"Nassim KAMAR, Pr","05 61 77 22 33","kamar.n@chu-toulouse.fr",{"facility":199,"status":36,"city":200,"state":10,"zip":10,"country":38,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"CHU Tours","Tours",{"type":40,"coordinates":202},[203,204],0.70398,47.39484,{"lat":204,"lon":203},[207],{"name":208,"role":26,"phone":209,"phoneExt":10,"email":210},"Matthias BUCHLER, Pr","02 47 47 47 47","buchler@med.univ-tours.fr",{"type":212,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100554833",false,"NCT06504225","EVEROLD LONG TERM FOLLOW-UP","Long-term Evaluation of the Value of Using an MTor Inhibitor (everolimus) for the Minimisation of Anticalceurins in Old-for-old Kidney Transplantation","EVEROLD FUP","Inclusion Criteria:\n\n* Informed patients participating to the EVEROLD study\n* Patient having completed the EVEROLD M12 follow-up visit\n* Patient agreeing to participate in the observational study\n\nExclusion Criteria:\n\n* Opposition to the use his medical data\n* Patient under legal protection","ALL","18 Years",{"count":223,"type":224},260,"ESTIMATED","OBSERVATIONAL","Long Term Follow up of EVEROLD study",[228],"Transplant; Complication, Failure","2025-02-04",{"date":231,"type":232},"2025-02-06","ACTUAL",{"date":234,"type":232},"2024-08-23",{"date":236,"type":224},"2025-08-01",{"name":5,"class":6},14]